Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
BRISBANE, Calif., Aug. 11, 2017 -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced that Cameron Durrant, MD, chairman and CEO, has been named a PharmaVOICE 100 Red Jacket Award honoree as part of the annual PharmaVOICE 100.
The PharmaVOICE 100 Red Jacket Award is a prestigious annual distinction that serves as a ‘hall of fame’ for executives who have been recognized multiple times in the PharmaVOICE 100, the publication’s annual list of inspiring industry leaders. PharmaVOICE 100 Red Jacket Award winners are selected as individuals who have shown a new kind of leadership, such as driving new ways of thinking, acting and leading; creating new opportunities from the ‘impossible’; having persistence of vision; and inspiring leaders for today and tomorrow.
“I am honored and grateful to be inducted into such an influential circle of leaders as the PharmaVOICE 100 Red Jacket Award,” said Dr. Durrant. “Finding new ways forward requires the persistence and resilience to execute and deliver them. This honor reflects the determination and forward-thinking mindset of our talented team at Humanigen, as we continue to execute on our priorities to help neglected and rare disease patients.”
Since January 2016, Dr. Durrant has led the transformation of Humanigen through significant operational, reputational and legal hurdles. Dr. Durrant is a five-time PharmaVOICE 100 honoree. To read the 2017 PharmaVOICE 100 Red Jacket Award profiles, visit www.pharmavoice.com.
About Humanigen
Humanigen, Inc. is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative, accelerated business models. Lead compounds in the portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). For more information, visit www.humanigen.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
